Fig. 5

Associations of phosphoflow cytometry signaling with outcome in breast cancer patients. In panels A-B, IL-6 signaling response was assessed in peripheral blood CD4⁺ naïve T cells prior to any therapy. The delta median fluorescent intensity (ΔMFI) in p-STAT1 and p-STAT3 response to IL-6 was assessed between non-relapsed and relapsed patients A. The signaling responsiveness (ΔMFI) above and below the median was also compared by Kaplan–Meier analysis to assess relapse-free survival B. In panels C-E, IFN-γ signaling response was assessed in peripheral monocytes from breast cancer patients prior to therapy. IFN-γ p-STAT1 signaling responsiveness in peripheral blood monocytes of breast cancer patients associates with relapse and relapse-free survival. MFI of pSTAT1 in monocytes stimulated with IFN-γ minus unstimulated in relapsed and relapsed-free breast cancer patients compared to healthy donors (HD) C. MFI of IFNγR1 on monocytes in relapsed and relapsed-free breast cancer patients compared to healthy donors D. Kaplan–Meier survival curves of relapse-free survival (RFS) between patients with high (≥ 25% quantile) vs low (< 25% quantile) IFN-γ responsiveness in both a discovery and validation cohort E. Panels A and B are modified from Wang et al., Cancer Res. 2017 [19]. Copyright© 2017. American Association for Cancer Research. Panels C-E are modified from Wang et al., EBioMedicine 2020 [48]. © Wang et al. Published by Elsevier B.V